Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines

Anne Julienne Genuino, Usa Chaikledkaew, Anna Melissa Guerrero, Thanyanan Reungwetwattana, Ammarin Thakkinstian

At its current cost, 1 year of adjuvant trastuzumab therapy compared to standard chemotherapy alone for HER2-positive EBC does not represent value for money ...